Unsafe testosterone-based dosing regimen of androgen deprivation therapy in patients with locally advanced or metastatic prostate cancer: a prematurely ended randomized controlled trial (MIDAS-trial)

Acta Oncol. 2021 Apr;60(4):539-543. doi: 10.1080/0284186X.2020.1862908. Epub 2020 Dec 26.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Androgen Antagonists* / adverse effects
  • Androgens / therapeutic use
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Humans
  • Male
  • Prostate-Specific Antigen
  • Prostatic Neoplasms* / drug therapy
  • Testosterone

Substances

  • Androgen Antagonists
  • Androgens
  • Antineoplastic Agents, Hormonal
  • Testosterone
  • Prostate-Specific Antigen